Citation: Cillessen SA, Hijmering NJ, Moesbergen LM, Vos W, Verbrugge SE, Jansen G, Visser OJ, Oudejans JJ, and Meijer CJ. ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. Haematologica. 2015; 100:xxx doi:10.3324/haematol.2014.118828 Publisher's Disclaimer. Figure 2B ). Experiments with specific caspase-9 inhibitor, LEHD-fmk demonstrated that the observed cell death was caspase-9 dependent in most ALCL cell lines, except for Karpas 299 (Figure 2A ). Sensitivity to bortezomib was not or less dependent on caspase-8 activation (data not shown). These findings suggest that bortezomib-induced apoptosis in ALCL mainly involves activation of the intrinsic apoptosis pathway which is consistent with a report in four ALCL cell lines.
Clinical outcome in anaplastic large cell lymphoma (ALCL), especially in systemic anaplastic lymphoma kinase (ALK)-negative ALCL is frequently poor despite intensive therapy regimens including CHOP (vincristine, doxorubicin, cyclophosphamide and prednisone), with or without etoposide. Although promising results have been obtained with targeted therapies such as brentuximab-vedotin, alemtuzumab and/or stem cell transplantation, alternative therapies are needed, which can improve patient outcome. 1, 2 Recent studies have demonstrated that expression levels of many NF-κB regulated antiapoptotic proteins are elevated in ALCL.
3,4,5 NF-κB activity can be inhibited by the proteasome inhibitor bortezomib resulting in induction of apoptosis. 6 Bortezomib has shown remarkable (pre)clinical anti-tumor activity in various types of cancer and was approved by the FDA for treatment of multiple myeloma and mantle cell lymphoma. In the present study,
we therefore investigated if bortezomib can induce apoptosis of primary lymphoma cells from ALK-negative and ALK-positive ALCL patients and in ALCL cell lines.
Cultured lymphoma cells 7 of five patients with systemic ALCL were exposed to increasing Figure 2B ). Experiments with specific caspase-9 inhibitor, LEHD-fmk demonstrated that the observed cell death was caspase-9 dependent in most ALCL cell lines, except for Karpas 299 (Figure 2A ). Sensitivity to bortezomib was not or less dependent on caspase-8 activation (data not shown). These findings suggest that bortezomib-induced apoptosis in ALCL mainly involves activation of the intrinsic apoptosis pathway which is consistent with a report in four ALCL cell lines. 8 Subsequently, we analyzed the effect of bortezomib on the levels of 34 apoptosis-inhibiting and apoptosis-inducing genes implicated in the intrinsic apoptosis pathway using RT-MLPA analysis, (see Supplemental Table I ). The most striking accumulation was observed of the BH3-only gene Noxa and this was already detectable after 7 hours of incubation ( Figure 2C ).
Bortezomib-induced upregulation of Noxa seemed to be higher in highly bortezomib-sensitive Using western blot analysis we could confirm the mRNA expression levels with actual protein expression levels ( Figure 3A ). Bortezomib increased the expression of MCL1-long, however the expression of the different pro-apoptotic proteins is apparently sufficient for the triggering of apoptosis. This is in agreement with previous studies in mantle cell lymphoma and cutaneous T-cell lymphoma. 10,11 MCL1 has a short half-life and is rapidly degraded by the proteasome. Accumulation of MCL1 in ALCL cells might be due to decrease of proteasomal degradation and/or caspase-3-dependent MCL1 protein cleavage. 12 However in our study, Figure 3E) . A recent study in lymphoid cells has shown that Noxa might be an eligible candidate for this interaction, since it is also able to bind to Bcl-2.
15
In conclusion, our preclinical data support the potential use of bortezomib as a therapeutic agent in ALK-negative ALCL and also might provide a rationale for the design of new bortezomib combination therapies for treatment of ALCL patients to improve their prognosis.
In vivo studies in human ALCL xenografts and clinical trials in patients with ALCL have to confirm that bortezomib is effective in ALCL, as the microenvironment of ALCL tumor cells might contribute to sensitivity to bortezomib. Moreover, mechanisms by which bortezomib upregulates Noxa expression have to be elucidated in further studies and might provide clinically available biomarkers, which can predict sensitivity to bortezomib in each patient. antibody. Expression levels of co-precipitating Bax were analyzed using western blot analysis.
SUPPLEMENTARY INFORMATION Supplementary Methods

Lymphoma patient samples and cell lines
Cells from five primary systemic ALCL, which were classified according to the World Health Organization (WHO) at the Comprehensive Cancer Center of Amsterdam, were included in this study. 1 All protocols for obtaining and studying human tissues and patients' data were 
Proteasome activity assay
The chymotryptic proteolytic activity of the proteasome was measured using a Proteasome-GLO assay kit (Promega, Madison, USA) as described previously. 3 Briefly, cells were incubated with a luminogenic substrate specific for chypmotrypsin-like protease activity for 10 minutes at room temperature (RT). Subsequently, luminescence was determined using a microplate reader (Tecan, Giessen, The Netherlands).
Assessment of cell death
Primary Cell death of primary cells and ALCL cell lines was determined as described previously. (DakoCytomation, Glostrup, Denmark) and on size (forward scatter, FSC).
Detection of caspase 3/7 activity
Caspase 3/7 activity was determined using a luminescent assay (Caspase-Glo TM 3/7 assay, Promega Benelux, Leiden, Netherlands). Cells were lysed and incubated with the DEVDcontaining substrate for 35 minutes at RT. Subsequently, luminescence was measured using a microplate luminometer (Victor2TM, Wallac, Perkin Elmer, Boston, MA, USA). Caspase activity was determined as caspase 3/7 activity levels of treated samples minus caspase 3/7 activity levels of untreated samples.
Measurement of Δψ m
Depolarization of the mitochondrial membrane (Ψ m ) was detected using the fluorescent probe tetramethylrhodamine ethyl ester perchlorate (TMRE, Invitrogen, Eugene, OR, USA) which accumulates in mitochondria. Briefly, cells (10 6 cells/ml) were incubated with 25nM TMRE at 37°C for 15 minutes in the dark and analyzed using FACS analysis. Mitochondrial membrane depolarization was observed as a shift to the left in the emission spectra. ΔΨ m was determined as the percentage unstained cells in bortezomib treated samples minus the percentage unstained cells in untreated samples.
RT-MLPA analysis
ALCL patient cells were isolated based on their phenotype using FACSsorting. Reverse
Transcriptase-Multiplex Ligation-dependent Probe Amplification (RT-MLPA) was performed on total RNA as described previously. 7, 8 For detailed description of the design of the 40 probes, (including 34 genes implicated in the intrinsic apoptosis pathway): www.mrcholland.com. Data were analyzed using GeneMapper (Applied Biosystems, Warrington, UK) and Coffalyser 7 (MRC-Holland, Amsterdam, the Netherlands) software. The ß-glucuronidase (GUS-B) housekeeping gene was used as internal reference. --Expression of Bcl-G, Harakiri, cIAP1 and BIRC7 were undetectable in the majority of cases and were excluded from further analysis. --, weak decrease; -, equal; +, weak increase; ++, moderate increase; +++, strong increase; in expression after exposure to bortezomib. /, variable expression between different cell lines and/or patient samples 
siRNA analysis
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